z-logo
open-access-imgOpen Access
Prednisolone andMycobacterium indicus praniiin Tuberculous Pericarditis
Author(s) -
Bongani M. Mayosi,
Mpiko Ntsekhe,
Jackie Bosch,
Shaheen Pandie,
Hyejung Jung,
Freedom Gumedze,
Janice Pogue,
Lehana Thabane,
Marek Smieja,
Veronica Francis,
Laura Joldersma,
Kandithalal M. Thomas,
Baby Thomas,
A A Awotedu,
Nombulelo Magula,
D.P. Naidoo,
Albertino Damasceno,
Alfred Chitsa Banda,
Basil Brown,
Pravin Manga,
Bruce Kirenga,
Charles Mondo,
Phindile Mntla,
Jacob M. Tsitsi,
Ferande Peters,
Mohammed R. Essop,
James B. Russell,
James Hakim,
Jonathan Matenga,
Ayub Felix Barasa,
Mahmoud U. Sani,
Taiwo Olunuga,
Okechukwu S. Ogah,
Victor Ansa,
Akinyemi Aje,
Solomon Danbauchi,
Dike Ojji,
Salim Yusuf
Publication year - 2014
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1407380
Subject(s) - medicine , hazard ratio , prednisolone , placebo , pericarditis , tuberculous pericarditis , gastroenterology , surgery , confidence interval , pathology , alternative medicine
Tuberculous pericarditis is associated with high morbidity and mortality even if antituberculosis therapy is administered. We evaluated the effects of adjunctive glucocorticoid therapy and Mycobacterium indicus pranii immunotherapy in patients with tuberculous pericarditis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom